AAT	alpha1-antitrypsin
AD	Alzheimer’s disease
ADMA	asymmetric dimethylarginine
APO	apolipoprotein
ASL	arterial spin labelling
Aβ	amyloid-beta
Bax	BCL2 associated X protein
BBB	blood–brain barrier
Bcl-2	B-cell lymphoma 2
BDNF	brain-derived neurotrophic factor
CAA	cerebral amyloid angiopathy
CADASIL	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CBF	cerebral blood flow
CNS	central nervous system
CSF	cerebrospinal fluid
DMA	dimethylarginine
FDG	18-fluorodeoxyglucose
GABA	gamma-amino-butyric acid
G-CSF	granulocyte-colony stimulating factor
H-FABP	heart-type fatty acid binding protein
ICF	intracortical facilitation
IFN-γ	interferon-gamma
IL	interleukin
LBD	Lewy body dementia
L-DOPA	levo-3,4-dihydroxyphenylalanine
MCI	mild cognitive impairment
MIP-1β	macrophage inflammatory protein 1beta
MMP	matrix metalloproteinases
MMSE	Mini Mental State Examination
MRI	magnetic resonance imaging
MRS	magnetic resonance spectroscopy
NF-L	neurofilament-light protein
NO	nitric oxide
PAI-1	plasminogen activator inhibitor 1
PAS	paired associative stimulation
PET	positron emission tomography
PIB	Pittsburgh compound B
P-tau	phosphorilated tau
rMT	resting motor threshold
rTMS	repetitive transcranial magnetic stimulation
SAI	short-latency afferent inhibition
SIVD	subcortical ischemic vascular disease
TCD	transcranial Doppler ultrasound
TIMP-1	tissue inhibitors of metalloproteinases 1
TMS	transcranial magnetic stimulation
TNF-α	tumor necrosis factor alpha
T-tau	total tau
VaD	vascular dementia
VCI	vascular cognitive impairment
VGLUT1	vesicular glutamate transporter 1
WMLs	white matter lesions